Expression of Insulinoma-Associated Protein 1 (INSM1) and Orthopedia Homeobox (OTP) in Tumors with Neuroendocrine Differentiation at Rare Sites
Insulinoma-associated protein 1 (INSM1) and orthopedia homeobox (OTP) are transcription factors that play a critical role in neuroendocrine (NE) and neuroepithelial cell development. INSM1 has been identified in multiple tumors of NE or neuroepithelial origin, whereas OTP expression has been mainly studied in NE tumors of pulmonary origin. Expression of OTP appears to correlate with poorer prognosis in pulmonary carcinoids; however, its expression patterns in other NE/neuroepithelial tumors need further investigation. Here, we assessed the diagnostic utility of INSM1 and OTP in tumors with NE differentiation at relatively uncommon sites including prostate, breast, and tumors of gynecologic origin. Thirty-two formalin-fixed, paraffin-embedded cases were used to construct a tissue microarray. Immunohistochemistry for INSM1 and OTP was performed and scored semi-quantitatively. INSM1 was diffusely expressed in 60% of gynecologic tumors, 71.4% of mammary carcinoma, and 25% of prostate adenocarcinoma with NE differentiation. Diffuse expression of OTP was detected in 50% of prostate adenocarcinoma with NE differentiation and 100% neuroendocrine carcinoma of the ovary. Immunostain for achaete-scute homolog 1, chromogranin, synaptophysin, and CD56 supported the NE and/or neuroepithelial differentiation of the tumors. In summary, INSM1 is expressed in most of the tumors with NE and neuroepithelial differentiation in this study, confirming the diagnostic utility of INSM1 as a novel and sensitive marker of NE/neuroepithelial differentiation. The expression of OTP in some NE tumors outside of lung expands the spectrum of tumors that may express this biomarker and should be considered when working up a NE tumor of unknown primary site.
KeywordsInsulinoma-associated protein 1 (INSM1) Orthopedia homeobox (OTP) Ovarian carcinoma with neuroendocrine differentiation Breast carcinoma with neuroendocrine differentiation Prostate carcinoma with neuroendocrine differentiation
The authors thank members of the TRIP Laboratory at UW SMPH.
The study was supported by an award from UW Carbone Cancer Center Neuroendocrine Cancer Research Task Force and the Aly Wolff Memorial Fund for Neuroendocrine Carcinoma Research.
- 10.Fujino, K., Motooka Y., Hassan W.A., Ali Abdalla M.O., Sato Y., Kudoh S., Hasegawa K., Niimori-Kita K., Kobayashi H., Kubota I., Wakimoto J., Suzuki M., Ito T., Insulinoma-Associated Protein 1 Is a Crucial Regulator of Neuroendocrine Differentiation in Lung Cancer. Am J Pathol, 2015. 185(12): p. 3164–3177.CrossRefGoogle Scholar
- 15.Tang, F., Wei B., Tian Z., Gilcrease M.Z., Huo L., Albarracin C.T., Resetkova E., Zhang H., Sahin A., Chen J., Bu H., Abraham S., Wu Y., Invasive mammary carcinoma with neuroendocrine differentiation: histological features and diagnostic challenges. Histopathology, 2011. 59(1): p. 106–115.CrossRefGoogle Scholar
- 21.Kuji, S., Watanabe R., Sato Y., Iwata T., Hirashima Y., Takekuma M., Ito I., Abe M., Nagashio R., Omae K., Aoki D., Kameya T., A new marker, insulinoma-associated protein 1 (INSM1), for high-grade neuroendocrine carcinoma of the uterine cervix: Analysis of 37 cases. Gynecologic Oncology, 2017. 144(2): p. 384–390.CrossRefGoogle Scholar
- 24.Clarke, B.A., Witkowski L., Ton Nu T.N., Shaw P.A., Gilks C.B., Huntsman D., Karnezis A.N., Sebire N., Lamovec J., Roth L.M., Stewart C.J.R., Hasselblatt M., Foulkes W.D., McCluggage W.G., Loss of SMARCA4 (BRG1) protein expression as determined by immunohistochemistry in small-cell carcinoma of the ovary, hypercalcaemic type distinguishes these tumours from their mimics. Histopathology, 2016. 69(5): p. 727–738.CrossRefGoogle Scholar
- 27.Xue, W., et al., Insulinoma-associated protein 1 is a novel sensitive and specific marker for small cell carcinoma of the prostate. Hum Pathol, 2018.Google Scholar
- 30.La Rosa, S., et al., Achaete-scute homolog 1 as a marker of poorly differentiated neuroendocrine carcinomas of different sites: a validation study using immunohistochemistry and quantitative real-time polymerase chain reaction on 335 cases. Hum Pathol, 2013. 44(7): p. 1391–1399.CrossRefGoogle Scholar